[Impact of SIRT1 gene expression on the development and treatment of the metabolic syndrome in oncological patients].
Sirtuins - products of gene SIRT expression have been divided into 7 classes, according to the amino acid composition and location of the cell. Those factors, called longevities proteins, are a group of histone deacetylases, depend on nicotinamide adenine dinucleotide (NAD). Particularly noteworthy is the protein sirtuin 1, which further deacetylates numerous transcription factors, receptors and enzymes. Through its action reduces the activity of glucocorticoid receptors in the body. Products of gene SIRT1 expression is responsible for apoptosis, differentiation, senescence cells, also affect the regulation of carbohydrate and lipid metabolism. Cardioprotective and hypotensive impact is also very important. SIRT1 reduces the accumulation of fat and decreases the risk of visceral obesity. Low gene expression of SIRT1 therefore predispose to the development of metabolic syndrome. Homeostasis sirtuin 1 disorders can also be observed in certain neoplastic diseases, primarily hormone-dependent breast, ovarian and prostate cancer, as well as it can cause leukemias and lymphomas. Components, activating expression of gen SIRT1 or a molecule with biological properties sirtuin 1, may have promising impact for treatment of diabetes mellitus type 2, obesity, hypertension, dyslipidemia. Analyzing, the pleiotropic effect of sirtuin 1 and numerous metabolic pathways, appear to be particularly beneficial effect of supplementation molecules increasing the level of expression gene SIRT1, in treatment of acute lymphoblastic leukemia with using high-dosing glicocorticosteroid therapy. Which would reduce the number of early and late complications of oncological treatment and increase patient survival. Compound requires further study.